# A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

> **NCT07540338** · PHASE1,PHASE2 · RECRUITING · sponsor: **Alzamend Neuro, Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** AL001
- **DRUG:** Lithium carbonate

## Key facts

- **NCT ID:** NCT07540338
- **Lead sponsor:** Alzamend Neuro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07540338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07540338, "A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07540338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*